PHASE II TRIAL OF NINTEDANIB IN PATIENTS WITH BEVACIZUMAB-RESISTANT RECURRENT EPITHELIAL OVARIAN, TUBAL, AND PERITONEAL CANCER
Publication
, Conference
Secord, AA; McCollum, M; Davidson, B; Broadwater, G; Squatrito, R; Havrilesky, L; Gabel, A; Nixon, A; Duska, L
Published in: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
September 1, 2018
Duke Scholars
Published In
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
EISSN
1525-1438
ISSN
1048-891X
Publication Date
September 1, 2018
Volume
28
Start / End Page
457 / 457
Publisher
BMJ PUBLISHING GROUP
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Secord, A. A., McCollum, M., Davidson, B., Broadwater, G., Squatrito, R., Havrilesky, L., … Duska, L. (2018). PHASE II TRIAL OF NINTEDANIB IN PATIENTS WITH BEVACIZUMAB-RESISTANT RECURRENT EPITHELIAL OVARIAN, TUBAL, AND PERITONEAL CANCER. In INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (Vol. 28, pp. 457–457). BMJ PUBLISHING GROUP.
Published In
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
EISSN
1525-1438
ISSN
1048-891X
Publication Date
September 1, 2018
Volume
28
Start / End Page
457 / 457
Publisher
BMJ PUBLISHING GROUP
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis